Camurus AB (FRA:7CA) Common Stock: €0.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7CA Camurus AB FRA:7CA
82 GF Score
Price €57.55
GF Value €61.90
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Camurus AB Common Stock?

Camurus AB FRA:7CA +2.31% 82 Common Stock is €0.1 Mil as of Jun. 2026. GuruFocus rates FRA:7CA with a GF Score™ of 82/100 and a GF Value™ of €61.90 (Fairly Valued). The stock has 2 warning signs investors should review.

Camurus AB's quarterly common stock increased from Dec. 2025 (€0.1 Mil) to Mar. 2026 (€0.1 Mil) but then declined from Mar. 2026 (€0.1 Mil) to Jun. 2026 (€0.1 Mil).

Camurus AB's annual common stock increased from Dec. 2023 (€0.1 Mil) to Dec. 2024 (€0.1 Mil) and increased from Dec. 2024 (€0.1 Mil) to Dec. 2025 (€0.1 Mil).

Camurus AB Common Stock Historical Data

* Premium members only.

The historical data trend for Camurus AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB Common Stock Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.13 0.12 0.13 0.14

Camurus AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.14 0.14 0.14
FRA:7CA
82GF Score
Camurus AB FRA:7CA
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camurus AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0.1 Mil mean?
Camurus AB (FRA:7CA) has a Common Stock of €0.1 Mil as of Jun. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Camurus AB and its competitors.
Is Camurus AB's Common Stock too high?
Camurus AB's current Common Stock is €0.1 Mil. Overall, Camurus AB has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Common Stock compare to VRTX and REGN?
Camurus AB's Common Stock of €0.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Camurus AB and its competitors. Camurus AB's current Common Stock is €0.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (FRA:7CA) is currently considered Fairly Valued. The stock's GF Value™ is €61.90, compared to a current price of €57.55 — trading 7% below its estimated fair value. The current Common Stock is €0.1 Mil. Camurus AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Camurus AB (FRA:7CA), the current Common Stock is €0.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (FRA:7CA) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of €57.55 is trading 7% below its estimated GF Value™ of €61.90. GuruFocus considers Camurus AB to be Fairly Valued.

Key valuation signals for FRA:7CA:

  • Common Stock: €0.1 Mil
  • GF Value™: €61.90 vs. price of €57.55 (7% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the FRA:7CA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
82GF Score

Get the complete analysis for FRA:7CA

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€57.55
Price
€61.90
GF Value